Patents by Inventor Sung-Sau So

Sung-Sau So has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FACTOR XIA INHIBITORS
    Publication number: 20240101567
    Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Application
    Filed: January 24, 2022
    Publication date: March 28, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: John S. Debenham, Cheng Zhu, Amjad Ali, Sung-Sau So, Ying-Duo Gao
  • FACTOR XI ACTIVATION INHIBITORS
    Publication number: 20230147170
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XI activation inhibitors.
    Type: Application
    Filed: March 26, 2021
    Publication date: May 11, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Jacqueline D. Hicks, Amjad Ali, John S. Debenham, Anthony Donofrio, Wenlang Fu, Ying-Duo Gao, Alan Hruza, Yeon-Hee Lim, Matthew J. Lombardo, Peter Nizner, Sung-Sau So, Zheng Tan, Daniel A. Tatosian, Dong Xiao, Dexi Yang, Yang Yu
  • FACTOR XI ACTIVATION INHIBITORS
    Publication number: 20220235033
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XI activation inhibitors.
    Type: Application
    Filed: May 26, 2020
    Publication date: July 28, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jacqueline D. Hicks, John S. Debenham, Amjad Ali, Lan Wei, Tianying Jian, Dexi Yang, Anthony K. Ogawa, Wenlang Fu, Matthew Lombardo, Rongze Kuang, Meng Yang, Sung-Sau So, Kenneth Ellsworth, Peter Nizner, Daniel A. Tatosian, Robert R. Wilkening, Jun Wang
  • Inhibitors of bruton's tyrosine kinase
    Patent number: 11104668
    Abstract: This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula (I) and at least one carrier, diluent or excipient.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: August 31, 2021
    Assignees: Hoffmann-La Roche Inc., Chugai Pharmaceutical Co.
    Inventors: Francisco Javier Lopez-Tapia, Sung-Sau So, Qi Qiao, Romyr Dominique
  • Factor XIIa inhibitors
    Patent number: 11014920
    Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: May 25, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jacqueline D. Hicks, Brian Alexander McKittrick, Brent R. Whitehead, Matthew Lombardo, Xiaoqing Han, Jerry A. Taylor, Hong Dong Chu, Sung-Sau So, Peter Orth, Zhicai Wu
  • ARGINASE INHIBITORS AND METHODS OF USE
    Publication number: 20210040127
    Abstract: Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.
    Type: Application
    Filed: March 8, 2019
    Publication date: February 11, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Abdelghani Abe Achab, Matthew L. Childers, Jared N. Cumming, Christian A. Fischer, Symon Gathiaka, Hakan Gunaydin, Charles A. Lesburg, Derun Li, Min Lu, Anandan Palani, Rachel L. Palte, Qinglin Pu, David L. Sloman, Sung-Sau So, Chunrui Sun, Hongjun Zhang
  • Factor XIIa inhibitors
    Patent number: 10875851
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: December 29, 2020
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Ashwin U. Rao, Brian Alexander McKittrick, Matthew Lombardo, Jacqueline D. Hicks, Amy Bittner McCracken, Hong Dong Chu, Sung-Sau So, Peter Orth, Zhicai Wu, Ping Lan, John S. Debenham, Brent R. Whitehead, Jerry A. Taylor, Zhongxiang Sun, Revathi Reddy Katipally, Jonathan E. Gable, Markus K. Dahlgren, Sathesh P. Bhat
  • Factor XIIa Inhibitors
    Publication number: 20200262831
    Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors.
    Type: Application
    Filed: November 13, 2017
    Publication date: August 20, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jacqueline D. Hicks, Brian Alexander McKittrick, Brent R. Whitehead, Matthew Lombardo, Xiaoqing Han, Jerry A. Taylor, Hong Dong Chu, Sung-Sau So, Peter Orth, Zhicai Wu
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20200207741
    Abstract: This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases onused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula (I) and at least one carrier, diluent or excipient.
    Type: Application
    Filed: March 11, 2020
    Publication date: July 2, 2020
    Inventors: Francisco Javier Lopez-Tapia, Sung-Sau So, Qi Qiao, Romyr Dominique
  • PYRAZOLE CARBOXAMIDE COMPOUNDS AND METHODS OF USE
    Publication number: 20200181154
    Abstract: Pyrazole carboxamide compounds of Formula I are provided, with various substituents, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk, and for treating cancer and immune disorders such as inflammation mediated by Btk. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: February 12, 2020
    Publication date: June 11, 2020
    Applicant: Genentech, Inc.
    Inventors: Roland J. BILLEDEAU, James J. CRAWFORD, Saul JAIME-FIGUEROA, Wendy LEE, Francisco Javier LOPEZ-TAPIA, Sung-Sau SO
  • Inhibitors of bruton's tyrosine kinase
    Patent number: 10640491
    Abstract: This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula (I) and at least one carrier, diluent or excipient.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: May 5, 2020
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Francisco Javier Lopez-Tapia, Sung-Sau So, Qi Qiao, Romyr Dominique
  • Factor XIIa Inhibitors
    Publication number: 20190352294
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors.
    Type: Application
    Filed: November 13, 2017
    Publication date: November 21, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Ashwin U. Rao, Brian Alexander McKittrick, Matthew Lombardo, Jacqueline D. Hicks, Amy Bittner McCracken, Hong Dong Chu, Sung-Sau So, Peter Orth, Zhicai Wu, Ping Lan, John S. Debenham, Brent R. Whitehead, Jerry A. Taylor, Zhongxiang Sun, Revathi Reddy Katipally, Jonathan E. Gable, Markus K. Dahlgren, Sathesh P. Bhat
  • PYRAZOLE CARBOXAMIDE COMPOUNDS AND METHODS OF USE
    Publication number: 20190194209
    Abstract: Pyrazole carboxamide compounds of Formula I are provided, with various substituents, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk, and for treating cancer and immune disorders such as inflammation mediated by Btk. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: February 28, 2019
    Publication date: June 27, 2019
    Applicant: Genentech, Inc.
    Inventors: Roland J. BILLEDEAU, James J. CRAWFORD, Saul JAIME-FIGUEROA, Wendy LEE, Francisco Javier LOPEZ-TAPIA, Sung-Sau SO
  • Factor XIa inhibitors
    Patent number: 10123995
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: November 13, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Eric Mertz, Weiguo Liu, Scott D. Edmondson, Amjad Ali, Ying-Duo Gao, Santhosh F. Neelamkavil, Sung-Sau So, Remond Moningka, Wanying Sun, Alan Hruza, Linda L. Brockunier
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20180305340
    Abstract: This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula (I) and at least one carrier, diluent or excipient.
    Type: Application
    Filed: June 26, 2018
    Publication date: October 25, 2018
    Inventors: Francisco Javier Lopez-Tapia, Sung-Sau So, Qi Qiao, Romyr Dominique
  • Inhibitors of bruton's tyrosine kinase
    Patent number: 10093657
    Abstract: This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula (I) and at least one carrier, diluent or excipient.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: October 9, 2018
    Assignees: HOFFMANN-LA ROCHE INC., CHUGAI PHARMACEUTICAL CO.
    Inventors: Francisco Javier Lopez-Tapia, Sung-Sau So, Qi Qiao, Romyr Dominique
  • Factor XIa inhibitors
    Patent number: 10081617
    Abstract: The present invention provides a compound of Formula (I); and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: September 25, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Eric Mertz, Scott D. Edmondson, Sung-Sau So, Wanying Sun, Weiguo Liu, Santhosh F. Neelamkavil, Ying-Duo Gao, Alan Hruza, Yi Zang, Amjad Ali, Rudrajit Mal, Jiafang He, Rongze Kuang, Heping Wu, Anthony K. Ogawa, Andrew F. Nolting
  • Factor XIa inhibitors
    Patent number: 10011585
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoaguability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: July 3, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Weiguo Liu, Scott D Edmondson, Zhuyan Guo, Alan Hruza, Sung-Sau So, Wanying Sun, Amjad Ali, Rongze Kuang, Ying-Duo Gao, Anthony K Ogawa
  • Factor XIa inhibitors
    Patent number: 9975874
    Abstract: The present invention provides a compound of Formula (I) (Formula (I)) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: May 22, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Eric Mertz, Scott D. Edmondson, Alan Hruza, Jiafang He, Sung-Sau So, Amjad Ali, Ying-Duo Gao
  • FACTOR XIa INHIBITORS
    Publication number: 20180079743
    Abstract: The present invention provides a compound of Formula (I); and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Application
    Filed: April 11, 2016
    Publication date: March 22, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Eric Mertz, Scott D. Edmondson, Sung-Sau So, Wanying Sun, Weiguo Liu, Santhosh F. Neelamkavil, Ying-Duo Gao, Alan Hruza, Yi Zang, Amjad Ali, Rudrajit Mal, Jiafang He, Rongze Kuang, Heping Wu, Anthony K. Ogawa, Andrew F. Nolting